Durvalumab was associated with a 27% reduction in the risk for death compared with placebo in the phase 3 ADRIATIC trial.
If approved, durvalumab will be the first and only perioperative immunotherapy regimen available for the treatment of ...
The US Food and Drug Administration (FDA) has approved AstraZeneca's human monoclonal antibody, Imfinzi (durvalumab), to ...
The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...
The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has ...
The FDA has approved Imfinzi (durvalumab) to treat LS-SCLC that has not progressed after concurrent platinum-based chemotherapy and radiation.
The government had issued notifications to reduce basic customs duty (BCD) to zero on these three drugs/formulations, apart ...
AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) has been accepted and granted Priority Review in the US for the treatment of patients with muscle-invasive ...
The approval of durvalumab, based on data from the phase 3 ADRIATIC study, offers a new standard of care for patients with ...
Patients experienced similar safety and efficacy if they received first-line or later-line treatment for unresectable ...
Accompanying these findings is a call for refined treatment strategies that have potential to better outcomes among patients ...
AstraZeneca’s IMFINZI® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following ...